Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

@article{Lamers2013TreatmentOM,
  title={Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.},
  author={Cor H J Lamers and Stefan Sleijfer and Sabine C. L. van Steenbergen and Pascal M M L van Elzakker and Brigitte A van Krimpen and Corrien Groot and Arnold Vulto and Michael A den Bakker and Egbert Oosterwijk and Reno Debets and Jan Willem C. Gratama},
  journal={Molecular therapy : the journal of the American Society of Gene Therapy},
  year={2013},
  volume={21 4},
  pages={904-12}
}
Autologous T cells genetically modified to express a chimeric antibody receptor (CAR) against carboxy-anhydrase-IX (CAIX) were administered to 12 patients with CAIX-expressing metastatic renal cell carcinoma (RCC). Patients were treated in three cohorts with a maximum of 10 infusions of a total of 0.2 to 2.1 × 10(9) CAR T cells. CTC grade 2-4 liver enzyme disturbances occurred at the lowest CAR T cell doses, necessitating cessation of treatment in four out of eight patients in cohorts 1 and 2… CONTINUE READING